PubMed:10373522 JSONTXT

{"project":"PMID_GLOBAL","denotations":[{"id":"T1","span":{"begin":960,"end":969},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":1361,"end":1370},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0000605"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0000605"}],"text":"p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes.\nIn T lymphocytes, the hematopoietic cytokine interleukin-2 (IL-2) uses phosphatidylinositol 3-kinase (PI 3-kinase)-induced signaling pathways to regulate E2F transcriptional activity, a critical cell cycle checkpoint. PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin. This immunosuppressive drug is known to prevent T-cell proliferation, but the precise point at which rapamycin regulates T-cell cycle progression has yet to be elucidated. Moreover, the effects of rapamycin on, and the role of p70(s6k) in, IL-2 and PI 3-kinase activation of E2Fs have not been characterized. Our present results show that IL-2- and PI 3-kinase-induced pathways for the regulation of E2F transcriptional activity include both rapamycin-resistant and rapamycin-sensitive components. Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses. Thus, the rapamycin-controlled processes involved in E2F regulation appear to be mediated by p70(s6k). However, the rapamycin-resistant p70(s6k) could not rescue rapamycin inhibition of T-cell cycle entry, consistent with the involvement of additional, rapamycin-sensitive pathways in the control of T-cell cycle progression. The present results thus show that p70(s6k) is able to regulate E2F transcriptional activity and provide direct evidence for the first time for a link between IL-2 receptors, PI 3-kinase, and p70(s6k) that regulates a crucial G1 checkpoint in T lymphocytes."}

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"protein"},{"id":"T2","span":{"begin":20,"end":49},"obj":"protein"},{"id":"T3","span":{"begin":86,"end":89},"obj":"protein"},{"id":"T4","span":{"begin":104,"end":117},"obj":"cell_type"},{"id":"T5","span":{"begin":122,"end":135},"obj":"cell_type"},{"id":"T6","span":{"begin":141,"end":163},"obj":"protein"},{"id":"T7","span":{"begin":164,"end":177},"obj":"protein"},{"id":"T8","span":{"begin":179,"end":183},"obj":"protein"},{"id":"T9","span":{"begin":190,"end":219},"obj":"protein"},{"id":"T10","span":{"begin":221,"end":232},"obj":"protein"},{"id":"T11","span":{"begin":273,"end":276},"obj":"protein"},{"id":"T12","span":{"begin":337,"end":348},"obj":"protein"},{"id":"T13","span":{"begin":380,"end":388},"obj":"protein"},{"id":"T14","span":{"begin":394,"end":425},"obj":"protein"},{"id":"T15","span":{"begin":711,"end":719},"obj":"protein"},{"id":"T16","span":{"begin":724,"end":728},"obj":"protein"},{"id":"T17","span":{"begin":733,"end":744},"obj":"protein"},{"id":"T18","span":{"begin":759,"end":763},"obj":"protein"},{"id":"T19","span":{"begin":823,"end":827},"obj":"protein"},{"id":"T20","span":{"begin":833,"end":844},"obj":"protein"},{"id":"T21","span":{"begin":884,"end":887},"obj":"protein"},{"id":"T22","span":{"begin":998,"end":1024},"obj":"protein"},{"id":"T23","span":{"begin":1028,"end":1036},"obj":"protein"},{"id":"T24","span":{"begin":1040,"end":1047},"obj":"cell_type"},{"id":"T25","span":{"begin":1083,"end":1086},"obj":"protein"},{"id":"T26","span":{"begin":1151,"end":1154},"obj":"protein"},{"id":"T27","span":{"begin":1191,"end":1199},"obj":"protein"},{"id":"T28","span":{"begin":1214,"end":1242},"obj":"protein"},{"id":"T29","span":{"begin":1459,"end":1467},"obj":"protein"},{"id":"T30","span":{"begin":1488,"end":1491},"obj":"protein"},{"id":"T31","span":{"begin":1583,"end":1587},"obj":"protein"},{"id":"T32","span":{"begin":1599,"end":1610},"obj":"protein"},{"id":"T33","span":{"begin":1616,"end":1624},"obj":"protein"},{"id":"T34","span":{"begin":1667,"end":1680},"obj":"cell_type"}],"text":"p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes.\nIn T lymphocytes, the hematopoietic cytokine interleukin-2 (IL-2) uses phosphatidylinositol 3-kinase (PI 3-kinase)-induced signaling pathways to regulate E2F transcriptional activity, a critical cell cycle checkpoint. PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin. This immunosuppressive drug is known to prevent T-cell proliferation, but the precise point at which rapamycin regulates T-cell cycle progression has yet to be elucidated. Moreover, the effects of rapamycin on, and the role of p70(s6k) in, IL-2 and PI 3-kinase activation of E2Fs have not been characterized. Our present results show that IL-2- and PI 3-kinase-induced pathways for the regulation of E2F transcriptional activity include both rapamycin-resistant and rapamycin-sensitive components. Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses. Thus, the rapamycin-controlled processes involved in E2F regulation appear to be mediated by p70(s6k). However, the rapamycin-resistant p70(s6k) could not rescue rapamycin inhibition of T-cell cycle entry, consistent with the involvement of additional, rapamycin-sensitive pathways in the control of T-cell cycle progression. The present results thus show that p70(s6k) is able to regulate E2F transcriptional activity and provide direct evidence for the first time for a link between IL-2 receptors, PI 3-kinase, and p70(s6k) that regulates a crucial G1 checkpoint in T lymphocytes."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":118},"obj":"Sentence"},{"id":"S2","span":{"begin":119,"end":336},"obj":"Sentence"},{"id":"S3","span":{"begin":337,"end":483},"obj":"Sentence"},{"id":"S4","span":{"begin":484,"end":655},"obj":"Sentence"},{"id":"S5","span":{"begin":656,"end":792},"obj":"Sentence"},{"id":"S6","span":{"begin":793,"end":981},"obj":"Sentence"},{"id":"S7","span":{"begin":982,"end":1097},"obj":"Sentence"},{"id":"S8","span":{"begin":1098,"end":1200},"obj":"Sentence"},{"id":"S9","span":{"begin":1201,"end":1423},"obj":"Sentence"},{"id":"S10","span":{"begin":1424,"end":1681},"obj":"Sentence"}],"text":"p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes.\nIn T lymphocytes, the hematopoietic cytokine interleukin-2 (IL-2) uses phosphatidylinositol 3-kinase (PI 3-kinase)-induced signaling pathways to regulate E2F transcriptional activity, a critical cell cycle checkpoint. PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin. This immunosuppressive drug is known to prevent T-cell proliferation, but the precise point at which rapamycin regulates T-cell cycle progression has yet to be elucidated. Moreover, the effects of rapamycin on, and the role of p70(s6k) in, IL-2 and PI 3-kinase activation of E2Fs have not been characterized. Our present results show that IL-2- and PI 3-kinase-induced pathways for the regulation of E2F transcriptional activity include both rapamycin-resistant and rapamycin-sensitive components. Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses. Thus, the rapamycin-controlled processes involved in E2F regulation appear to be mediated by p70(s6k). However, the rapamycin-resistant p70(s6k) could not rescue rapamycin inhibition of T-cell cycle entry, consistent with the involvement of additional, rapamycin-sensitive pathways in the control of T-cell cycle progression. The present results thus show that p70(s6k) is able to regulate E2F transcriptional activity and provide direct evidence for the first time for a link between IL-2 receptors, PI 3-kinase, and p70(s6k) that regulates a crucial G1 checkpoint in T lymphocytes."}

{"project":"genia-medco-coref","denotations":[{"id":"C1","span":{"begin":0,"end":8},"obj":"NP"},{"id":"C2","span":{"begin":20,"end":49},"obj":"NP"},{"id":"C3","span":{"begin":86,"end":100},"obj":"NP"},{"id":"C4","span":{"begin":104,"end":117},"obj":"NP"},{"id":"C5","span":{"begin":122,"end":135},"obj":"NP"},{"id":"C6","span":{"begin":273,"end":301},"obj":"NP"},{"id":"C7","span":{"begin":303,"end":335},"obj":"NP"},{"id":"C8","span":{"begin":337,"end":348},"obj":"NP"},{"id":"C9","span":{"begin":380,"end":388},"obj":"NP"},{"id":"C10","span":{"begin":390,"end":425},"obj":"NP"},{"id":"C11","span":{"begin":427,"end":437},"obj":"NP"},{"id":"C12","span":{"begin":438,"end":442},"obj":"NP"},{"id":"C13","span":{"begin":459,"end":482},"obj":"NP"},{"id":"C14","span":{"begin":484,"end":511},"obj":"NP"},{"id":"C15","span":{"begin":558,"end":575},"obj":"NP"},{"id":"C16","span":{"begin":579,"end":584},"obj":"NP"},{"id":"C17","span":{"begin":585,"end":594},"obj":"NP"},{"id":"C18","span":{"begin":605,"end":629},"obj":"NP"},{"id":"C19","span":{"begin":681,"end":690},"obj":"NP"},{"id":"C20","span":{"begin":711,"end":719},"obj":"NP"},{"id":"C22","span":{"begin":884,"end":912},"obj":"NP"},{"id":"C21","span":{"begin":866,"end":912},"obj":"NP"},{"id":"C23","span":{"begin":1028,"end":1036},"obj":"NP"},{"id":"C24","span":{"begin":1040,"end":1047},"obj":"NP"},{"id":"C25","span":{"begin":1151,"end":1165},"obj":"NP"},{"id":"C26","span":{"begin":1191,"end":1199},"obj":"NP"},{"id":"C27","span":{"begin":1398,"end":1422},"obj":"NP"},{"id":"C28","span":{"begin":1459,"end":1467},"obj":"NP"},{"id":"C29","span":{"begin":1488,"end":1516},"obj":"NP"},{"id":"C31","span":{"begin":1599,"end":1610},"obj":"NP"},{"id":"C32","span":{"begin":1616,"end":1624},"obj":"NP"},{"id":"C30","span":{"begin":1568,"end":1624},"obj":"NP"},{"id":"C33","span":{"begin":1625,"end":1629},"obj":"NP"},{"id":"C34","span":{"begin":1667,"end":1680},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C5","obj":"C4"},{"id":"R2","pred":"coref-appos","subj":"C7","obj":"C6"},{"id":"R3","pred":"coref-ident","subj":"C8","obj":"C2"},{"id":"R4","pred":"coref-ident","subj":"C9","obj":"C1"},{"id":"R5","pred":"coref-appos","subj":"C10","obj":"C9"},{"id":"R6","pred":"coref-relat","subj":"C12","obj":"C11"},{"id":"R7","pred":"coref-ident","subj":"C14","obj":"C13"},{"id":"R8","pred":"coref-relat","subj":"C16","obj":"C15"},{"id":"R9","pred":"coref-ident","subj":"C17","obj":"C14"},{"id":"R10","pred":"coref-ident","subj":"C19","obj":"C17"},{"id":"R11","pred":"coref-ident","subj":"C20","obj":"C9"},{"id":"R12","pred":"coref-ident","subj":"C22","obj":"C6"},{"id":"R13","pred":"coref-ident","subj":"C21","obj":"C3"},{"id":"R14","pred":"coref-ident","subj":"C23","obj":"C20"},{"id":"R15","pred":"coref-ident","subj":"C24","obj":"C5"},{"id":"R16","pred":"coref-ident","subj":"C25","obj":"C21"},{"id":"R17","pred":"coref-ident","subj":"C26","obj":"C23"},{"id":"R18","pred":"coref-ident","subj":"C27","obj":"C18"},{"id":"R19","pred":"coref-ident","subj":"C28","obj":"C26"},{"id":"R20","pred":"coref-ident","subj":"C29","obj":"C22"},{"id":"R21","pred":"coref-ident","subj":"C31","obj":"C8"},{"id":"R22","pred":"coref-ident","subj":"C32","obj":"C28"},{"id":"R23","pred":"coref-relat","subj":"C33","obj":"C30"},{"id":"R24","pred":"coref-ident","subj":"C34","obj":"C24"}],"text":"p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes.\nIn T lymphocytes, the hematopoietic cytokine interleukin-2 (IL-2) uses phosphatidylinositol 3-kinase (PI 3-kinase)-induced signaling pathways to regulate E2F transcriptional activity, a critical cell cycle checkpoint. PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin. This immunosuppressive drug is known to prevent T-cell proliferation, but the precise point at which rapamycin regulates T-cell cycle progression has yet to be elucidated. Moreover, the effects of rapamycin on, and the role of p70(s6k) in, IL-2 and PI 3-kinase activation of E2Fs have not been characterized. Our present results show that IL-2- and PI 3-kinase-induced pathways for the regulation of E2F transcriptional activity include both rapamycin-resistant and rapamycin-sensitive components. Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses. Thus, the rapamycin-controlled processes involved in E2F regulation appear to be mediated by p70(s6k). However, the rapamycin-resistant p70(s6k) could not rescue rapamycin inhibition of T-cell cycle entry, consistent with the involvement of additional, rapamycin-sensitive pathways in the control of T-cell cycle progression. The present results thus show that p70(s6k) is able to regulate E2F transcriptional activity and provide direct evidence for the first time for a link between IL-2 receptors, PI 3-kinase, and p70(s6k) that regulates a crucial G1 checkpoint in T lymphocytes."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":0,"end":8},"obj":"protein_molecule"},{"id":"T2","span":{"begin":20,"end":49},"obj":"protein_molecule"},{"id":"T3","span":{"begin":54,"end":81},"obj":"other_name"},{"id":"T4","span":{"begin":86,"end":89},"obj":"protein_molecule"},{"id":"T5","span":{"begin":104,"end":117},"obj":"cell_type"},{"id":"T6","span":{"begin":122,"end":135},"obj":"cell_type"},{"id":"T7","span":{"begin":141,"end":163},"obj":"protein_family_or_group"},{"id":"T8","span":{"begin":164,"end":177},"obj":"protein_molecule"},{"id":"T9","span":{"begin":179,"end":183},"obj":"protein_molecule"},{"id":"T10","span":{"begin":190,"end":219},"obj":"protein_molecule"},{"id":"T11","span":{"begin":221,"end":232},"obj":"protein_molecule"},{"id":"T12","span":{"begin":273,"end":276},"obj":"protein_molecule"},{"id":"T13","span":{"begin":314,"end":335},"obj":"other_name"},{"id":"T14","span":{"begin":337,"end":348},"obj":"protein_molecule"},{"id":"T15","span":{"begin":380,"end":388},"obj":"protein_molecule"},{"id":"T16","span":{"begin":394,"end":425},"obj":"protein_molecule"},{"id":"T17","span":{"begin":463,"end":472},"obj":"other_organic_compound"},{"id":"T18","span":{"begin":473,"end":482},"obj":"other_organic_compound"},{"id":"T19","span":{"begin":489,"end":511},"obj":"other_organic_compound"},{"id":"T20","span":{"begin":532,"end":552},"obj":"other_name"},{"id":"T21","span":{"begin":585,"end":594},"obj":"other_organic_compound"},{"id":"T22","span":{"begin":605,"end":629},"obj":"other_name"},{"id":"T23","span":{"begin":681,"end":690},"obj":"other_organic_compound"},{"id":"T24","span":{"begin":711,"end":719},"obj":"protein_molecule"},{"id":"T25","span":{"begin":724,"end":728},"obj":"protein_molecule"},{"id":"T26","span":{"begin":733,"end":744},"obj":"protein_molecule"},{"id":"T27","span":{"begin":759,"end":763},"obj":"protein_family_or_group"},{"id":"T28","span":{"begin":823,"end":827},"obj":"protein_molecule"},{"id":"T29","span":{"begin":833,"end":844},"obj":"protein_molecule"},{"id":"T30","span":{"begin":884,"end":887},"obj":"protein_molecule"},{"id":"T31","span":{"begin":998,"end":1007},"obj":"other_organic_compound"},{"id":"T32","span":{"begin":1028,"end":1036},"obj":"protein_molecule"},{"id":"T33","span":{"begin":1040,"end":1047},"obj":"cell_type"},{"id":"T34","span":{"begin":1062,"end":1071},"obj":"other_organic_compound"},{"id":"T35","span":{"begin":1083,"end":1086},"obj":"protein_molecule"},{"id":"T36","span":{"begin":1108,"end":1117},"obj":"other_organic_compound"},{"id":"T37","span":{"begin":1151,"end":1154},"obj":"protein_molecule"},{"id":"T38","span":{"begin":1191,"end":1199},"obj":"protein_molecule"},{"id":"T39","span":{"begin":1214,"end":1223},"obj":"other_organic_compound"},{"id":"T40","span":{"begin":1234,"end":1242},"obj":"protein_molecule"},{"id":"T41","span":{"begin":1260,"end":1269},"obj":"other_organic_compound"},{"id":"T42","span":{"begin":1351,"end":1360},"obj":"other_organic_compound"},{"id":"T43","span":{"begin":1398,"end":1422},"obj":"other_name"},{"id":"T44","span":{"begin":1459,"end":1467},"obj":"protein_molecule"},{"id":"T45","span":{"begin":1488,"end":1491},"obj":"protein_molecule"},{"id":"T46","span":{"begin":1583,"end":1587},"obj":"protein_molecule"},{"id":"T47","span":{"begin":1599,"end":1610},"obj":"protein_molecule"},{"id":"T48","span":{"begin":1616,"end":1624},"obj":"protein_molecule"},{"id":"T49","span":{"begin":1650,"end":1663},"obj":"other_name"},{"id":"T50","span":{"begin":1667,"end":1680},"obj":"cell_type"}],"text":"p70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes.\nIn T lymphocytes, the hematopoietic cytokine interleukin-2 (IL-2) uses phosphatidylinositol 3-kinase (PI 3-kinase)-induced signaling pathways to regulate E2F transcriptional activity, a critical cell cycle checkpoint. PI 3-kinase also regulates the activity of p70(s6k), the 40S ribosomal protein S6 kinase, a response that is abrogated by the macrolide rapamycin. This immunosuppressive drug is known to prevent T-cell proliferation, but the precise point at which rapamycin regulates T-cell cycle progression has yet to be elucidated. Moreover, the effects of rapamycin on, and the role of p70(s6k) in, IL-2 and PI 3-kinase activation of E2Fs have not been characterized. Our present results show that IL-2- and PI 3-kinase-induced pathways for the regulation of E2F transcriptional activity include both rapamycin-resistant and rapamycin-sensitive components. Expression of a rapamycin-resistant mutant of p70(s6k) in T cells could restore rapamycin-suppressed E2F responses. Thus, the rapamycin-controlled processes involved in E2F regulation appear to be mediated by p70(s6k). However, the rapamycin-resistant p70(s6k) could not rescue rapamycin inhibition of T-cell cycle entry, consistent with the involvement of additional, rapamycin-sensitive pathways in the control of T-cell cycle progression. The present results thus show that p70(s6k) is able to regulate E2F transcriptional activity and provide direct evidence for the first time for a link between IL-2 receptors, PI 3-kinase, and p70(s6k) that regulates a crucial G1 checkpoint in T lymphocytes."}